Jose Rios - Centogene Chief Officer
| CNTG Stock | USD 0.09 0.01 16.88% |
Insider
Jose Rios is Chief Officer of Centogene B V
| Age | 50 |
| Address | Am Strande 7, Rostock, Germany, 18055 |
| Phone | 49 381 80113 500 |
| Web | https://www.centogene.com |
Centogene Management Efficiency
The company has return on total asset (ROA) of (0.2676) % which means that it has lost $0.2676 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.7533) %, meaning that it created substantial loss on money invested by shareholders. Centogene's management efficiency ratios could be used to measure how well Centogene manages its routine affairs as well as how well it operates its assets and liabilities. The Centogene's current Return On Equity is estimated to increase to 1.44, while Return On Tangible Assets are projected to decrease to (0.52). At this time, Centogene's Other Assets are most likely to increase significantly in the upcoming years. The Centogene's current Other Current Assets is estimated to increase to about 5.3 M, while Non Current Assets Total are projected to decrease to roughly 32.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Guido Baechler | Mainz Biomed BV | 59 | |
| Jeffrey Eberwein | Star Equity Holdings | 53 | |
| William Caragol | Mainz Biomed BV | 57 | |
| John Boniface | Sera Prognostics | 62 | |
| David Noble | Star Equity Holdings | 52 | |
| Bobbi Coffin | Biodesix | N/A | |
| Gary Pestano | Biodesix | 57 | |
| MD Frcp | Aclaris Therapeutics | 63 | |
| Robert Doody | Aclaris Therapeutics | N/A | |
| Wim Criekinge | MDxHealth SA ADR | 52 | |
| Hannah Bible | Star Equity Holdings | 43 | |
| Matthew Molchan | Star Equity Holdings | 57 | |
| John Bellano | MDxHealth SA ADR | 55 | |
| Kimberly Beaty | Inotiv Inc | N/A | |
| Heinrich Rder | Biodesix | N/A | |
| Martin Shirley | Star Equity Holdings | 61 | |
| Kevin Theriault | Sotera Health Co | N/A | |
| Philipp Freese | Mainz Biomed BV | 41 | |
| Moritz Eidens | Mainz Biomed BV | 40 | |
| Thatcher Butcher | Star Equity Holdings | N/A | |
| Paul Changelian | Aclaris Therapeutics | N/A | |
Management Performance
| Return On Equity | -13.75 | ||||
| Return On Asset | -0.27 |
Centogene B V Leadership Team
Elected by the shareholders, the Centogene's board of directors comprises two types of representatives: Centogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Centogene. The board's role is to monitor Centogene's management team and ensure that shareholders' interests are well served. Centogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Centogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ian Rentsch, Chief Pharma | ||
| Peter MD, Chief Officer | ||
| Andrin MD, Advisor | ||
| Kim Stratton, CEO Board | ||
| Bettina Goerner, Chief Officer | ||
| Lennart Streibel, Director Projects | ||
| Florian Vogel, Chief Officer | ||
| Jose Rios, Chief Officer | ||
| Patrice Denefle, Chief Officer |
Centogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Centogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.75 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.73) % | ||||
| Operating Margin | (0.63) % | ||||
| Current Valuation | 67.82 M | ||||
| Shares Outstanding | 29 M | ||||
| Shares Owned By Insiders | 4.56 % | ||||
| Shares Owned By Institutions | 66.89 % | ||||
| Number Of Shares Shorted | 81.71 K | ||||
| Price To Earning | (6.69) X |
Currently Active Assets on Macroaxis
When determining whether Centogene B V is a strong investment it is important to analyze Centogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Centogene's future performance. For an informed investment choice regarding Centogene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centogene B V. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centogene. If investors know Centogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 1.723 | Quarterly Revenue Growth (0.08) | Return On Assets (0.27) | Return On Equity (13.75) |
The market value of Centogene B V is measured differently than its book value, which is the value of Centogene that is recorded on the company's balance sheet. Investors also form their own opinion of Centogene's value that differs from its market value or its book value, called intrinsic value, which is Centogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centogene's market value can be influenced by many factors that don't directly affect Centogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Centogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.